Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1
Completed · Phase 2 · Has a placebo group
Conditions studied: Myotonic Dystrophy Type 1
In brief
To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and quality of life endpoints in DM1 patients
Key facts
- Study ID
- NCT00577577
- Run by
- Insmed Incorporated
- People needed
- 69
- Starts
- 2007-12-01
- Expected to finish
- 2008-12-29
- Last updated by the study team
- 2022-01-06
Who can join
Age: 21 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California Irvine Medical Center; MDA, ALS and Neuromuscular Center — Orange, California, United States
- University of California, Davis — Sacramento, California, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Johns Hopkins Hospital — Baltimore, Maryland, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Washington University Medical School — St Louis, Missouri, United States
- University of Rochester, Neuromuscular Disease Center — Rochester, New York, United States
- Ohio State University Medical Center — Columbus, Ohio, United States
- Oregan Health and Science University — Portland, Oregon, United States
- Universit of Texas Medical Branch — Galveston, Texas, United States
- University of Texas Health Science Center — San Antonio, Texas, United States
- University of Utah — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.